Capricor Therapeutics(DE:4LN2)
€8.95+0.78 (+9.58%)
DE:4LN2
Capricor Therapeutics stock forecast
€8.95
At close:+0.78 (+9.58%)
Capricor Therapeutics (4LN2) Stock Forecast & Price Target
0 Followers
4LN2 Analyst Ratings
Moderate Buy
4Buy4Hold0Sell
Based on 8 analysts giving stock ratings to Capricor Therapeutics in the past 3 months
4LN2 Stock 12 Month Forecast
Average Price Target
€24.96▲(179.04% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is EUR 24.96 with a high forecast of EUR 48.66 and a low forecast of EUR 9.46. The average price target represents a 179.04% change from the last price of EUR 8.95.
Past 12 Months12 Month ForecastJan2026Oct2026
High€48.66
Average€24.96
Low€9.46
Highest Price TargetHighest€48.66Average Price Target€24.96Lowest Price TargetLowest€9.46
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Boobalan Pachaiyappan | Roth MKM | €6.31→€9.46 | hold | 5.77%Upside | Reiterated | 11/12/26 | ||
| Joseph Pantginis | H.C. Wainwright | ― | hold | ― | Reiterated | 11/11/26 | ||
| Leland Gershell | Oppenheimer | €48.66 | buy | 443.97%Upside | Reiterated | 11/11/26 | ||
| Edward Tenthoff | Piper Sandler | €22.53 | buy | 151.84%Upside | Reiterated | 11/11/26 | ||
| Madison Elsaadi | B. Riley Securities | €18.92 | buy | 111.54%Upside | Reiterated | 11/11/26 | ||
| Kristen Kluska | Cantor Fitzgerald | €25.23 | buy | 182.06%Upside | Reiterated | 11/10/26 | ||
| Catherine Novack | JonesTrading | ― | hold | ― | Reiterated | 09/27/26 | ||
| Jason McCarthy | Maxim Group | ― | hold | ― | Reiterated | 08/14/26 | ||
| Matthew Venezia | Alliance Global Partners | ― | hold | ― | Reiterated | 07/30/26 | ||
| Rick Bienkowski | Ladenburg Thalmann & Co. | ― | hold | ― | Downgraded | 07/30/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Boobalan PachaiyappanRoth MKM | HoldReiterated€6.31→€9.46 | 11/12/26 | 5.77%Upside | ||
| Joseph PantginisH.C. Wainwright | HoldReiterated | 11/11/26 | ― | ||
| Leland GershellOppenheimer | BuyReiterated€48.66 | 11/11/26 | 443.97%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiterated€22.53 | 11/11/26 | 151.84%Upside | ||
| Madison ElsaadiB. Riley Securities | BuyReiterated€18.92 | 11/11/26 | 111.54%Upside | ||
| Kristen KluskaCantor Fitzgerald | BuyReiterated€25.23 | 11/10/26 | 182.06%Upside | ||
| Catherine NovackJonesTrading | HoldReiterated | 09/27/26 | ― | ||
| Jason McCarthyMaxim Group | HoldReiterated | 08/14/26 | ― | ||
| Matthew VeneziaAlliance Global Partners | HoldReiterated | 07/30/26 | ― | ||
| Rick BienkowskiLadenburg Thalmann & Co. | HoldDowngraded | 07/30/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Capricor Therapeutics
3 Months
Success Rate7/15 ratings generated profit
47%
Average Return
+25.03%
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +25.03% per trade.
1 Year
Success Rate9/15 ratings generated profit
60%
Average Return
+61.84%
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +61.84% per trade.
2 Years
Success Rate5/15 ratings generated profit
33%
Average Return
+33.98%
Copying Kristen Kluska's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +33.98% per trade.
4LN2 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 15 | 7 | 7 | 4 | 6 |
| Buy | 4 | 1 | 1 | 0 | 0 |
| Hold | 10 | 17 | 18 | 10 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 29 | 25 | 26 | 14 | 11 |
In the current month, 4LN2 has received 6 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 4LN2 average Analyst price target in the past 3 months is 24.96.
4LN2 Financial Forecast
High€1.05
Consensus€-0.33
Low€-0.65
4LN2 Earnings Forecast
Next quarter’s earnings estimate for 4LN2 is -EUR 0.33 with a range of -EUR 0.65 to EUR 1.05. The previous quarter’s EPS was -EUR 0.65. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€271M
Consensus€47.2M
Low€0.00
4LN2 Sales Forecast
Next quarter’s sales forecast for 4LN2 is EUR 47.24M with a range of EUR 0 to EUR 271.09M. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
4LN2 Stock Forecast FAQ
What is DE:4LN2’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is €24.96.
What is DE:4LN2’s upside potential, based on the analysts’ average price target?
Capricor Therapeutics has 179.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Capricor Therapeutics a Buy, Sell or Hold?
Capricor Therapeutics has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.
What is Capricor Therapeutics’s share price target?
The average share price target for Capricor Therapeutics is €24.96. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €48.66, and the lowest forecast is €9.46. The average share price target represents a 179.04% increase from the current price of €8.946.
What do analysts say about Capricor Therapeutics?
Capricor Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of Capricor Therapeutics?
To buy shares of DE:4LN2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
